Literature DB >> 27423585

Hyperintensity of the corticospinal tract on FLAIR: A simple and sensitive objective upper motor neuron degeneration marker in clinically verified amyotrophic lateral sclerosis.

Jiaoting Jin1, Fangfang Hu1, Qiuli Zhang2, Rui Jia1, Jingxia Dang3.   

Abstract

OBJECTIVE: The involvement of upper motor neuron (UMN) degeneration is crucial to the diagnosis of amyotrophic lateral sclerosis (ALS). However, it is difficult to detect in the early stages, and particularly with predominantly lower motor neuron (LMN) dysfunction. Thus, objective and sensitive UMN degeneration markers are needed for an accurate and early diagnosis. Several studies have investigated the abnormal signal changes in brain MRI for patients with ALS, so we hope to develop a neuroimaging diagnosis method in brain MRI that can evaluate UMN degeneration.
MATERIALS AND METHODS: We investigated corticospinal tract (CST) hyperintensity on MRI-fluid attenuated inversion recovery (FLAIR) images for 82 clinically verified ALS patients and 38 age-and gender-matched control subjects. Visual evaluation of the FLAIR images was analyzed independently by 3 observers. The clinical examination was implemented by an experienced neurological physician.
RESULTS: The three observers' views were identical regarding CST hyperintensity on FLAIR images in subcortical precentral gyrus, centrum emiovale, internal capsule, and cerebral peduncles levels (p>0.05). The frequency of CST hyperintensity is significantly higher for the ALS group than the control group in subcortical precentral gyrus, centrum semiovale, posterior limbs of internal capsule and cerebral peduncles levels. (p<0.01). The mean areas under the receiver operating characteristic curves (AUC) values were not different among clinical examinations, CST hyperintensity and mixed-examination (CST hyperintensity and clinical examination groups) in subcortical precentral gyrus, centrum semiovale, internal capsule, and cerebral peduncles levels (p>0.05), although AUC values of CST hyperintensity was slightly higher than clinical examination in centrum semiovale level. There was no statistically significant correlation between CST hyperintensity and age of onset, gender, disease duration, region of onset, and clinical UMN manifestation. (p>0.05).
CONCLUSION: CST hyperintensity was found more frequently in patients with ALS compared to the matched control group. It can be used to evaluate UMN degeneration effectively in subcortical precentral gyrus, centrum semiovale and cerebral peduncles levels. Combining CST hyperintensity and clinical examination can improve the sensitivity of diagnostic performance for UMN degeneration in ALS.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Hyperintensity of corticospinal tract; Upper motor neuron degeneration

Mesh:

Year:  2016        PMID: 27423585     DOI: 10.1016/j.jns.2016.06.005

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders.

Authors:  Conor Fearon; Sapna Rawal; Diana Olszewska; Paula Alcaide-Leon; Drew S Kern; Soumya Sharma; Shyam K Jaiswal; Jagarlapudi M K Murthy; Ainhi D Ha; Raymond S Schwartz; Victor S C Fung; Chauncey Spears; Tracy Tholanikunnel; Leonardo Almeida; Taku Hatano; Yutaka Oji; Nobutaka Hattori; Shantanu Shubham; Hrishikesh Kumar; Roongroj Bhidayasiri; Christopher Laohathai; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2022-02-03

2.  Alterations of Microstructure and Sodium Homeostasis in Fast Amyotrophic Lateral Sclerosis Progressors: A Brain DTI and Sodium MRI Study.

Authors:  M M El Mendili; A-M Grapperon; R Dintrich; J-P Stellmann; J-P Ranjeva; M Guye; A Verschueren; S Attarian; W Zaaraoui
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-30       Impact factor: 4.966

3.  An Unusual Case of Central Nervous System Lymphoma Presenting With Ataxic Quadriparesis Showing 'Wine glass'-Like Appearance.

Authors:  Byoung June Ahn; Heounjeong Go; Kyum-Yil Kwon
Journal:  J Clin Neurol       Date:  2022-05       Impact factor: 2.566

4.  T1 hyperintensity in the spinal cord: A diagnostic marker of amyotrophic lateral sclerosis?

Authors:  Vivek Pai; Chintan R Trivedi; Bhujang Pai; Saravana K Swaminathan
Journal:  J Clin Imaging Sci       Date:  2022-04-27

Review 5.  Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases. The Example of Amyotrophic Lateral Sclerosis.

Authors:  Miguel Mazón; Juan Francisco Vázquez Costa; Amadeo Ten-Esteve; Luis Martí-Bonmatí
Journal:  Front Neurosci       Date:  2018-10-25       Impact factor: 4.677

Review 6.  A review of cervical spine MRI in ALS patients.

Authors:  F Antonescu; M Adam; C Popa; S Tuţă
Journal:  J Med Life       Date:  2018 Apr-Jun

7.  Value of fluid-attenuated inversion recovery MRI data analyzed by the lesion segmentation toolbox in amyotrophic lateral sclerosis.

Authors:  Anna M Wirth; Siw Johannesen; Andrei Khomenko; Dobri Baldaranov; Tim-Henrik Bruun; Christina Wendl; Gerhard Schuierer; Mark W Greenlee; Ulrich Bogdahn
Journal:  J Magn Reson Imaging       Date:  2018-12-19       Impact factor: 4.813

8. 

Authors:  Ritwik Ghosh; Souvik Dutta; Mrinalkanti Ghosh; Julian Benito-Leon
Journal:  Neurologia       Date:  2022-02-04       Impact factor: 3.109

9.  Case Report: A 72-Year-Old Woman With Progressive Motor Weakness, Dry Eyes and High Levels of Serum Neurofilament Light Chain.

Authors:  Maria Janina Wendebourg; Jens Kuhle; Martin Hardmeier
Journal:  Front Neurol       Date:  2022-07-11       Impact factor: 4.086

10.  Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseases-A systematic review and meta-analysis.

Authors:  Charlotte Zejlon; Dominik Nakhostin; Sebastian Winklhofer; Athina Pangalu; Zsolt Kulcsar; Sebastian Lewandowski; Johannes Finnsson; Fredrik Piehl; Caroline Ingre; Tobias Granberg; Benjamin Victor Ineichen
Journal:  Front Neurol       Date:  2022-08-30       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.